Education
About Us
Working with TipRanks
Follow Us
Axim Biotech (AXIM)
:AXIM
AXIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume359.42K
Average Volume (3M)153.81K
Market Cap
$1.98M
Enterprise Value$9.64M
Total Cash (Recent Filing)$7.18K
Total Debt (Recent Filing)$7.38M
Price to Earnings (P/E)―
Beta0.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding301,958,830
10 Day Avg. Volume127,823
30 Day Avg. Volume153,814
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio28.54
Enterprise Value/Market Cap4.87
Enterprise Value/Revenue36.50
Enterprise Value/Gross Profit-46.78
Enterprise Value/Ebitda-0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AXIM Biotechnologies News
PremiumCompany Announcements
AXIM Biotechnologies Resolves Dispute, Issues EquityOptions Prices
Currently, No data available
---
Ownership Overview
9.47% Insiders
―
Mutual Funds
― Other Institutional Investors
90.53% Public Companies and
Individual Investors
AXIM FAQ
What was Axim Biotech’s price range in the past 12 months?
Axim Biotech lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Axim Biotech’s market cap?
Axim Biotech’s market cap is $1.98M.
When is Axim Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Axim Biotech’s earnings last quarter?
Currently, no data Available
Is Axim Biotech overvalued?
According to Wall Street analysts Axim Biotech’s price is currently Overvalued.
Does Axim Biotech pay dividends?
Axim Biotech does not currently pay dividends.
What is Axim Biotech’s EPS estimate?
Axim Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Axim Biotech have?
Axim Biotech has 301,958,830 shares outstanding.
What happened to Axim Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Axim Biotech?
Currently, no hedge funds are holding shares in AXIM
Company Description
Axim Biotech
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Biodexa Pharmaceuticals
―
Scorpius Holdings
―
Windtree Therapeutics
―
Universe Pharmaceuticals
―
Onconetix
―